Studies have demonstrated that elevated PD-1 and PD-L1 expression in tumor tissues is associated with reduced immune cell activity [15,25,26], which correlates with poor outcomes in cancers such as lung cancer [27], pancreatic cancer [28,29], and bladder cancer [30]. This evidence concerns the gene PDCD1 and urinary bladder cancer.